Literature DB >> 17258232

Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains.

O Holmes1, S Pillozzi, J A Deakin, F Carafoli, L Kemp, P J G Butler, M Lyon, E Gherardi.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF), the ligand for the receptor tyrosine kinase encoded by the c-Met proto-oncogene, is a multidomain protein structurally related to the pro-enzyme plasminogen and with major roles in development, tissue regeneration and cancer. We have expressed the N-terminal (N) domain, the four kringle domains (K1 to K4) and the serine proteinase homology domain (SP) of HGF/SF individually in yeast or mammalian cells and studied their ability to: (i) bind the Met receptor as well as heparan sulphate and dermatan sulphate co-receptors, (ii) activate Met in target cells and, (iii) map their binding sites onto the beta-propeller domain of Met. The N, K1 and SP domains bound Met directly with comparable affinities (K(d)=2.4, 3.3 and 1.4 microM). The same domains also bound heparin with decreasing affinities (N>K1>>SP) but only the N domain bound dermatan sulphate. Three kringle domains (K1, K2 and K4) displayed agonistic activity on target cells. In contrast, the N and SP domains, although capable of Met binding, displayed no or little activity. Further, cross-linking experiments demonstrated that both the N domain and kringles 1-2 bind the beta-chain moiety (amino acid residues 308-514) of the Met beta-propeller. In summary, the K1, K2 and K4 domains of HGF/SF are sufficient for Met activation, whereas the N and SP domains are not, although the latter domains contribute additional binding sites necessary for receptor activation by full length HGF/SF. The results provide new insights into the structure/function of HGF/SF and a basis for engineering the N and K1 domains as receptor antagonists for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258232     DOI: 10.1016/j.jmb.2006.12.061

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  36 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Alternative proteolytic processing of hepatocyte growth factor during wound repair.

Authors:  Nils Buchstein; Daniel Hoffmann; Hans Smola; Sabina Lang; Mats Paulsson; Catherin Niemann; Thomas Krieg; Sabine A Eming
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

Review 3.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.

Authors:  Prasanta K Hota; Matthias Buck
Journal:  Cell Mol Life Sci       Date:  2012-06-29       Impact factor: 9.261

4.  An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.

Authors:  Cassie J Liu; Douglas S Jones; Ping-Chuan Tsai; Abhishek Venkataramana; Jennifer R Cochran
Journal:  FEBS Lett       Date:  2014-11-21       Impact factor: 4.124

5.  Structural basis for agonism and antagonism of hepatocyte growth factor.

Authors:  W David Tolbert; Jennifer Daugherty-Holtrop; Ermanno Gherardi; George Vande Woude; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

6.  The regulatory role of heparin on c-Met signaling in hepatocellular carcinoma cells.

Authors:  Evin İşcan; Aysim Güneş; Peyda Korhan; Yeliz Yılmaz; Esra Erdal; Neşe Atabey
Journal:  J Cell Commun Signal       Date:  2016-12-14       Impact factor: 5.782

7.  Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.

Authors:  Tong-Chao Liu; Xia Peng; Yu-Chi Ma; Yin-Chun Ji; Dan-Qi Chen; Ming-Yue Zheng; Dong-Mei Zhao; Mao-Sheng Cheng; Mei-Yu Geng; Jing-Kang Shen; Jing Ai; Bing Xiong
Journal:  Acta Pharmacol Sin       Date:  2016-04-04       Impact factor: 6.150

8.  Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor.

Authors:  Toby Passioura; Hiroki Sato; Katsuya Sakai; Kenichiro Ito; Hiroki Furuhashi; Masataka Umitsu; Junichi Takagi; Yukinari Kato; Hidefumi Mukai; Shota Warashina; Maki Zouda; Yasuyoshi Watanabe; Seiji Yano; Mikihiro Shibata; Hiroaki Suga; Kunio Matsumoto
Journal:  Nat Chem Biol       Date:  2019-05-17       Impact factor: 15.040

9.  HGF and MET mutations in primary and secondary lymphedema.

Authors:  David N Finegold; Vivien Schacht; Mark A Kimak; Elizabeth C Lawrence; Etelka Foeldi; Jenny M Karlsson; Catherine J Baty; Robert E Ferrell
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

10.  Molecular magnetic resonance imaging approaches used to aid in the understanding of the tissue regeneration marker Met in vivo: implications for tissue engineering.

Authors:  Rheal A Towner; Nataliya Smith; Yasuko Asano; Sabrina Doblas; Debra Saunders; Robert Silasi-Mansat; Florea Lupu
Journal:  Tissue Eng Part A       Date:  2010-02       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.